Kamada (KMDA) Research & Development (2012 - 2026)
Kamada's (KMDA) quarterly Research & Development came in at $2.2 million in Q2 2026, down 31.66% on a YoY basis from $3.2 million in Q2 2025, and up 0.87% quarter-over-quarter from $2.2 million in Q1 2026.
Analysis
Kamada (KMDA) Research & Development (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Research & Development for 15 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Research & Development fell 31.66% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $9.9 million (down 26.87% YoY), and the FY2025 full-year result was $13.0 million, down 14.42% from the prior year.
- Research & Development improved to $2.2 million in Q2 2026 per KMDA's latest filing, from $2.2 million in the prior quarter.
- Across five years, Research & Development topped out at $4.8 million in Q2 2024 and bottomed at $2.2 million in Q1 2026.
- Historically, Research & Development has averaged $3.3 million across 5 years, with a median of $3.2 million in 2023.
- The sharpest annual moves came in 2022 and 2026: Research & Development jumped 68.19% in 2022, then plunged 48.63% in 2026.
- Over 5 years, Research & Development stood at $3.0 million in 2022, then increased by 8.29% to $3.2 million in 2023, then decreased by 17.47% to $2.7 million in 2024, then rose by 8.27% to $2.9 million in 2025, then dropped by 23.98% to $2.2 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $2.2 million, $2.2 million, and $2.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Kamada | 473.28 Mn | 403.14 Mn | 22.47 Mn | 2.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.20 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.64 Mn |
| Jun 30, 2025 | 3.22 Mn |
| Mar 31, 2025 | 4.25 Mn |
| Dec 31, 2024 | 2.67 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 4.80 Mn |
| Mar 31, 2024 | 4.30 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.18 Mn |
| Jun 30, 2023 | 4.28 Mn |
| Mar 31, 2023 | 3.23 Mn |
| Dec 31, 2022 | 2.99 Mn |
| Sep 30, 2022 | 3.12 Mn |
| Jun 30, 2022 | 2.64 Mn |
| Mar 31, 2022 | 4.42 Mn |
| Dec 31, 2021 | 3.45 Mn |
| Sep 30, 2021 | 2.55 Mn |